Neurosterix completes $105 million Series B financing, Addex’s stake diluted to 8.5%
Addex Therapeutics announced that its spin‑out Neurosterix closed a $105 million Series B round. Addex’s equity interest was reduced to an 8.5% stake valued at $18.6 million. The proceeds will fund Phase 2 development of NTX‑253, a muscarinic M4 positive allosteric modulator for schizophrenia. After the announcement, Addex shares jumped more than 110% in overnight trading.
Why it matters
The financing provides Neurosterix with capital to advance its lead schizophrenia program, which could create future upside for Addex as a shareholder (the company noted the stake value of $18.6 million). The market reaction, a 110.08% surge in Addex’s stock, reflects investor optimism about the program’s potential.
Key facts
- 1Neurosterix closed a $105 million Series B financing. finanznachrichten.de
- 2Addex’s equity interest in Neurosterix now represents 8.5% of the issued capital. finanznachrichten.de
- 3The 8.5% stake is valued at $18.6 million. finanznachrichten.de
- 4The financing will primarily support Phase 2 clinical development of NTX‑253 for schizophrenia. finanznachrichten.de
- 5Addex’s stock surged 110.08% in overnight trading, reaching $6.00. rttnews.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.